Centessa Q3 2023 net loss $38.6M; cash $281.3M, SerpinPC data at ASH

Centessa Pharmaceuticals plc

2023-Q3 EPS reported -$1.20

Cash and investments $281.3M as of Sep 30, 2023; expected to fund operations into 2026.
Net loss of $38.6M vs $53.9M in Q3 2022; R&D expense $28.2M, down 23% YoY.
SerpinPC Phase 2a Part 5 data accepted for ASH poster Dec 10; PRESent-2 and PRESent-3 registrational studies ongoing.
ORX750 (OX2R agonist) preclinical data support best-in-class profile for narcolepsy; IND-enabling studies underway, clinical proof-of-concept data planned for 2024.
LockBody platform: LB101 (PD-L1xCD47) Phase 1/2a ongoing; LB206 (PD-L1xCD3) development candidate selected in August.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Centessa Pharmaceuticals plc reported the third quarter ended September 30, 2023 results: net income $38.6 million.

Period: the third quarter ended September 30, 2023
Net income: $38.6 million
Result: reported results

Exact text from the filing

Centessa Pharmaceuticals plc (the “Company”) announced its financial results for the quarter ended September 30, 2023.

View on SEC.gov

59 earnings releases filed in the last 30 days. Browse all earnings releases →

Centessa Pharmaceuticals plc filing history →

Source: SEC EDGAR

accession 0001847903-23-000187

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.